A convenient synthesis of 1,3,4-thiadiazole and 1,3,4-oxadiazole based peptidomimetics employing diacylhydrazines derived from amino acids by Nagendra, G. et al.
Tetrahedron Letters 51 (2010) 6338–6341Contents lists available at ScienceDirect
Tetrahedron Letters
journal homepage: www.elsevier .com/ locate / tet letA convenient synthesis of 1,3,4-thiadiazole and 1,3,4-oxadiazole based
peptidomimetics employing diacylhydrazines derived from amino acids
G. Nagendra, Ravi S. Lamani, N. Narendra, Vommina V. Sureshbabu ⇑
Peptide Research Laboratory, Department of Studies in Chemistry, Central College Campus, Dr. B. R. Ambedkar Veedhi, Bangalore University, Bangalore 560 001, India
a r t i c l e i n f oArticle history:
Received 30 August 2010
Revised 23 September 2010
Accepted 25 September 2010
Keywords:
Peptidomimetics
Diacylhydrazine
Cyclization
Thiadiazole
Oxadiazole0040-4039/$ - see front matter  2010 Elsevier Ltd. A
doi:10.1016/j.tetlet.2010.09.122
⇑ Corresponding author. Tel.: +91 08 2296 1339/09
E-mail addresses: sureshbabuvommina@rediffm
hariccb@hotmail.com (V.V. Sureshbabu).a b s t r a c t
Synthesis of novel orthogonally protected 1,3,4-thiadiazole and 1,3,4-oxadiazole tethered dipeptide
mimetics is described. Both the heterocycles are prepared via a set of diacylhydrazines derived from
amino acids. 1,3,4-Thiadiazoles are synthesized by dehydrosulfurization using Lawesson’s reagent while
1,3,4-oxadiazoles are obtained by EDC mediated cyclodehydration.
 2010 Elsevier Ltd. All rights reserved.The changes in conformation, polarity and metabolic stability
generated by structural modiﬁcations of peptide backbone have
prompted the synthesis of several new classes of peptide mimics,
which contain unnatural linkages as replacements for the native
peptide bonds. These molecules have shown enhanced potency,
speciﬁcity and oral bioavailability than the natural peptides and
are considered to be potential candidates in drug discovery.1 One
such important class of molecules is peptides substituted with het-
erocycles, also referred to as peptide heterocycles. The heterocyclic
unit in these molecules can introduce conformational constraints
to the structure that enhances the activity and alters the struc-
ture–activity-relationships.2 Thus several heterocycles such as
1,2,3- and 1,2,4-triazole,3 oxazole,4 thiazole, and tetrazole,5 have
been inserted en route to the design of new peptidomimetics. 2-Al-
kyl amino-1,3,4-oxadiazole based peptidomimetics have been de-
scribed earlier by our group.6 In view of the above and as a part
of our ongoing work on the synthesis of amino acids and peptide
derivatives containing heterocyclic units,7 we herein report the
facile synthesis of novel N,N0-orthogonally protected 1,3,4-thi-
adiazolo- and 1,3,4-oxadiazolo-substituted peptides. Substances
bearing these heterocycles have attracted signiﬁcant interest in
medicinal and bio-organic chemistry. For example, thiadiazole
derivatives are known to be potent aminopeptidase inhibitors8
and metalloprotease inhibitors.9 Similarly, biologically relevantll rights reserved.
986312937.
ail.com, hariccb@gmail.com,entities containing the oxadiazole motif include HIV integrase
inhibitors and the angiogenesis inhibitors.10,11
Although numerous reports are available for the construction of
1,2,4-oxadiazole peptidomimetics,7a,12 the reports on the synthesis
of 1,3,4-oxadiazole and 1,3,4-thiadiazoles containing peptides are
rare. Recently Katritzky et al.,13 described a related class of com-
pounds which are amino acid derivatives containing 2-alkyl
amino-1,3,4-thiadiazole units. The synthesis consisted of coupling
N-protected amino acid hydrazides with alkyl isothiocyanates fol-
lowed by dehydration of the resulting thiosemicarbazides. Several
others have reported the synthesis of molecules containing a 1,3,4-
thiadiazole unit starting from alkyl and aryl diacylhydrazines.14
The standard method for the synthesis of 1,3,4-thiadiazoles
involves cyclization of N0-(acyl)thiohydrazide15a or thiosemicar-
bazides15b employing usually POCl3, PCl5, MsOH, or H2SO4 as dehy-
drating agents. The other important route is via the exchange of
the oxygen atom in 1,3,4-oxadiazole to sulfur using thiourea and
tetraphosphorus decasulﬁde.16 Following the former route, Katri-
tzky et al.,13 have used H2SO4 for the cyclization of Na-Cbz pro-
tected amino acid derived thiosemicarbazides and have obtained
the thiadiazole products with concomitant removal of the Cbz-
group. We envisaged that the use of strong acidic conditions for
cyclization, apart from being harsh, is not suitable for amino acid
substrates when they bear acid sensitive protecting group(s). In
this regard, we sought a mild and effective route for the insertion
of 1,3,4-thiadiazole into peptides.
Luthman17 and co-workers reported the synthesis of Phe-Gly
dipeptidomimetics containing 1,3,4-oxadiazole and 1,2,4-oxadiaz-
ole and Gly mimetics containing 1,3,4-oxadiazoles18 through
Table 2
List of 1,3,4-thiadiazoles 4/oxadiazoles 5 prepared
Entry Mp (C) Yield (%) Mass
Calcd Obsd
4a 128 82 651.2253 651.2257b
5a 83 73 613.2662 613.2668a
4b Gum 94 593.2 593.3d
5b 131 81 555.2607 555.2610a
4c 123 90 593.2198 593.2196b
5c 148 86 577.2427 577.2426b
4d Gum 76 593.2 593.2d
5d 113 80 555.2641 555.2646a
4e 148 95 467.1787 467.1792a
5e Gum 91 451.2 451.2c
4f 197 83 647.3 647.8c
5f 56 81 631.3 631.2c
4g 152 96 633.2 633.3c
5g 141 88 639.2583 639.2588b
4h 78 83 586.2675 586.2679b
5h Gum 71 570.3 570.8d
4i 145 79 435.2 435.0c
5i 126 88 441.2 441.3d
4j Gum 90 340.1 340.8 c
5j 93 94 346.3357 346.3362b
a HRMS [M+H+].
b HRMS [M+Na+].
c ESI-MS [M+H+].
d ESI-MS [M+Na+].
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Scheme 2. Synthesis of 1,3,4-thiadiazoles 4 and 1,3,4-oxadiazoles 5. Reagents and
conditions: (a) LR, THF, reﬂux, 3 h, (b) EDC/TEA, DCM, reﬂux, 3 h.
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NHNH2 and methyl malonyl chloride. Huryn and co-workers,19
synthesized S-linked 2,5-disubstituted oxadiazoles through
chemoselective alkylation of oxadiazolethiones obtained from
Boc-Trp-NHNH2. Synthesis of amino acid derived oxadiazoles via
the dehydrothiolative cyclization of thiosemicarbazide has also
been reported.20 The present report deals with the synthesis of
1,3,4-thiadiazole and oxadiazole based peptidomimetics through
a facile route which involves N,N0-di-a-aminoacyl hydrazines as
common precursors.
The required diacylhydrazines were synthesized as follows. Ini-
tially, the N-Boc/Z-protected amino acids were converted to their
corresponding hydrazides 1 following the reported protocol.21 N-
Acylation of the latter with a second amino acid to furnish the dia-
cylhydrazine was achieved by the treatment with N-Boc/Z pro-
tected a-amino acid ﬂuorides. Unlike amino acid chlorides, N-
urethane protected amino acid ﬂuorides are excellent coupling re-
agents for both solution and solid phase synthesis. Their most
impressive application is in the synthesis of extremely hindered
dipeptides.22 The N-protected amino acid ﬂuorides 2 used were
prepared through the reaction of protected amino acids with
Deoxo-ﬂuor23 in the presence of N-methylmorpholine (NMM). In
a typical example, Fmoc-Ala-F was treated with Boc-Phe-NHNH2
in dry CH2Cl2 at room temperature for 30 min. The resulting pepti-
dyl diacylhydrazine 3bwas isolated and puriﬁed (Scheme 1).24 The
list of N-protected diacylhydrazines prepared is summarized in Ta-
ble 1.
Lawesson and co-workers, have described the thionation of 1,2-
diacylhydrazines with 2,4-bis(4-methoxypheny1)-1,2,3,4-dithiadi-
phosphetane (Lawesson’s reagent, LR), followed by spontaneous
ring closure through dehydrosulfurization leading to the formation
of thiadiazole ring.25 Their study dealt mainly with the preparation
of dialkyl thiadiazoles. We sought to extend this route for the syn-
thesis of thiadiazole tethered N,N0-orthogonally protected dipepti-
domimetics 4 through the direct cyclization of diacylhydrazines
(without the requirement of a separate thionation step).
In a typical experiment, the diacylhydrazine 3b was reﬂuxed
with LR in THF for 3 hwhich yielded the 1,3,4-thiadiazolo-dipeptide
4b. The sameprotocolwasused to prepare several differentially pro-
tected 1,3,4-thiadiazolo-peptides 4a–j containing N,N0-orthogonal
amino protecting groups (Scheme 2, Table 2, Fig 1).26
The synthesis of oxadiazolo-peptides 5a–j was then under-
taken. 1,3,4-Oxadiazoles have been synthesized by several ap-
proaches, involving dehydrocyclization of diacylhydrazines andPg1HN
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Scheme 1. Synthesis of diacylhydrazines 3.
Table 1
List of diacyl hydrazines 3 prepared
Compd Pg1 Amino acid (R1) Pg2
3a Boc Gly Fmoc
3b Boc Phe Fmoc
3c Boc Phe Fmoc
3d Boc Ile Z
3e Boc Ala Z
3f Z Phe Fmoc
3g Z Val Fmoc
3h Z Lys(Boc) Boc
Figure 1.oxidation of acylhydrazones. In the former route regents such as
Et2OBF3,27 hexamethyldisilazane,28 Tf2O,29 polyphosphoric acid,30
SOCl2. and POCl331 have been frequently used as dehydrating
agents for cyclization. However, the use of these reagents is not al-
ways compatible with amino acid/peptides due to their ability toAmino acid (R2) Mp (C) Yield (%)
Glu(Bzl) Gum 78
Ala 178 90
D-Ala 178 90
Cys(Bzl) 151 81
Met Gum 84
Leu 205 89
Phe 167 96
Ala 147 76
6340 G. Nagendra et al. / Tetrahedron Letters 51 (2010) 6338–6341cause undesired reactions like cleavage of protecting groups. The
mild reagents generally used are carbodiimides,32 TsCl/pyridine33,
trimethyl silylchloride34, and Burgess reagent.35 Therefore, we fo-
cused on employing ethyl-3-(3-dimethylaminoprophyl)carbodiim-
ide (EDC) as cyclodehydrating agent. EDC was particularly
attractive because of easy handling, simplicity associated to the
workup of the product, efﬁciency in terms of product yield and
the familiarity with its use in peptide and peptidomimetic(s) syn-
thesis. In a typical procedure, the reaction of the N-Boc, N0-Fmoc
protected diacylhydrazine 3b in dry CH2Cl2 was reﬂuxed in the
presence of 1 equiv of EDC and 1.5 equiv of triethylamine (TEA)
for 3 h which resulted in the formation of 1,3,4-oxadiazole deriva-
tive 5b in almost quantitative yield. Extending the protocol further,
a series of Boc, Z and Fmoc-protected 1,3,4-oxadiazole containing
dipeptidomimetics 5a–j were prepared starting from the corre-
sponding diacylhydrazides (Scheme 2, Table 2, Fig. 1).36
Using the above protocols, the 1,3,4-thiadiazole/oxadiazole
moieties were also inserted between an orthogonally protected
sterically hindered dipeptide Z-Aib-CONHNHCO-Aib-Boc (Fig. 1,
4i and 5i). In another example Z-Ala-CONHNH2 was coupled to
C6H5COF and subsequently cyclized into 1,3,4-thiadiazole/oxadiaz-
ole derivative (Fig. 1, 4j and 5j).
Finally, the possibility of racemization during the synthesis of
title thiadiazoles and oxadiazoles was studied by determination
of the chiral purity of the samples of 4b, 5b, 4c, and 5c prepared
via the present protocol by means of 1H NMR and HPLC analy-
ses.37,38 The studies revealed that the tested samples were opti-
cally homogenous, and further the described protocol is free
from racemization.
In conclusion, the current protocol is a simple and straightfor-
ward route for the insertion of 1,3,4-thiadiazolo- and 1,3,4-
oxadiazolo-units into peptides. The synthesis makes use of amino
acid substituted diacylhydrazines as common intermediate which
on treatment with Lawesson’s reagent and EDC furnishes the thi-
adiazolyl and oxadiazolyl compounds, respectively. The proce-
dures give good yields and good purities with no detectable
enantiomerization.
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